Cubist Pharmaceuticals Receives Average Rating of “Buy” from Brokerages (NASDAQ:CBST)
Cubist Pharmaceuticals (NASDAQ:CBST) has been given an average rating of “Buy” by the fourteen brokerages that are currently covering the company, Stock Ratings Network.com reports. Four research analysts have rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $80.91.
Cubist Pharmaceuticals (NASDAQ:CBST) opened at 61.05 on Wednesday. Cubist Pharmaceuticals has a 52-week low of $58.50 and a 52-week high of $82.12. The stock’s 50-day moving average is $66.90 and its 200-day moving average is $70.38. The company has a market cap of $4.614 billion and a P/E ratio of 534.21.
Cubist Pharmaceuticals (NASDAQ:CBST) last issued its quarterly earnings data on Tuesday, July 22nd. The company reported $0.23 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.01 by $0.22. The company had revenue of $294.40 million for the quarter, compared to the consensus estimate of $299.60 million. During the same quarter last year, the company posted $0.42 earnings per share. Cubist Pharmaceuticals’s revenue was up 13.8% compared to the same quarter last year. On average, analysts predict that Cubist Pharmaceuticals will post $0.71 earnings per share for the current fiscal year.
CBST has been the subject of a number of recent research reports. Analysts at JMP Securities downgraded shares of Cubist Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Wednesday, July 23rd. They now have a $80.00 price target on the stock. Separately, analysts at Aegis reiterated a “positive” rating on shares of Cubist Pharmaceuticals in a research note on Monday, June 23rd. Finally, analysts at Jefferies Group reiterated a “buy” rating on shares of Cubist Pharmaceuticals in a research note on Monday, June 23rd. They now have a $88.00 price target on the stock, up previously from $87.00.
In other Cubist Pharmaceuticals news, EVP Steven C. Gilman sold 40,625 shares of Cubist Pharmaceuticals stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $61.57, for a total transaction of $2,501,281.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Cubist Pharmaceuticals, Inc (NASDAQ:CBST) is a biopharmaceutical company focused on the research, development and commercialization of therapies to treat serious medical conditions in acutely ill patients who are hospitalized or are being treated in other acute care settings.
Receive News & Ratings for Cubist Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cubist Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.